Cancer immunotherapy startup Zumutor Biologics just landed $7.3 million, with Premji Invest joining Accel and Bharat Innovation Fund. This Series B pushes their lead drug, ZM008, into global Phase 2 trials, activating natural killer cells against tumors. It's a significant bet on a high-risk, high-reward biotech frontier aiming to reshape solid tumor treatment.
How We Got Here
Founded in 2013, Zumutor raised $6.2 million in its Series A4 round in 2021. The company began human trials for its lead drug ZM008 in 2024, with early Phase 1 data showing promising potential.
The Numbers
- The $7.3 Mn will complete the ongoing US FDA Phase 1 clinical study of ZM008, used both alone and in combination regimens.
- It will also fund Phase 1B expansion cohorts and global Phase 2 studies, with an India leg included.
- ZM008 is a "first-in-class NK cell checkpoint" designed to activate the body's natural killer (NK) cells against tumors.
- While Zumutor’s headquarters are in the US, its core R&D laboratory operates out of Bengaluru.
- This raise follows the central government's ₹10,000 Cr Biopharma SHAKTI scheme to boost the biotech sector.
What Happens Next
🇮🇳 Why This Matters for India
For Bengaluru's deep-tech researchers and biotech founders, this funding validates India's R&D capabilities in high-stakes oncology.
The Take
Premji Invest backing such a capital-intensive, long-gestation biotech venture signals a shift for Indian VCs. Expect more patient institutional capital to chase high-impact, deep-tech plays beyond pure software.
Source:
Inc42 ↗